Neurogenic overactive bladder: focus on cognitive function


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. An overactive bladder and cognitive impairment are two medical and social problems, which have an outmost importance, affecting the quality of life. Both disorders are common in the practice of a urologist, neurologist, internist, and other physicians. Parkinson’s disease and multiple sclerosis are the most common neurological diseases, which often manifest by pelvic dysfunction and cognitive dysfunction. The clinician needs to understand the pathogenesis of the underlying disease and the pharmacologic properties of drugs, which can be used both in neurology and urology, as well as in other related specialties. Aim. To evaluate cognitive functions in patients with neurogenic overactive bladder treated with trospium chloride. Materials and methods. A total of 45 patients with neurological disease (28 with Parkinson’s disease [group 1] and 17 with multiple sclerosis [group 2]) were included in the study. All patients had symptoms of an overactive bladder. Trospium chloride was administered in an individually adjusted dose for 12 weeks. Cognitive functions were assessed using the international Montreal Cognitive Assessment (MoCA) before and after the therapy. A change of total scores over time was assessed using the paired Wilcoxon test. The level of significance of <0.05 was used (confidence level of 95%). Results. A significant decrease in all studied parameters of an overactive bladder in both groups was seen. The baseline evaluation of the total score on the MoCA scale prior to the start of taking trospium chloride revealed the presence of moderate cognitive impairment (21.3±2.9 points) in patients of the group 1. After 12 weeks of therapy, no significant change in cognitive functions was observed (21.7±3.1 points; p>0.05). In group 2, moderate cognitive impairment (MoCA 22.5±3.7 points) was found at baseline. After taking trospium chloride, no significant changes were noted (MoCA 22.9±4.1 points) (p> 0.05). No central nervous system side effects were reported in any group. Conclusion. Trospium chloride is an effective drug, which does not affect cognitive functions in patients with neurogenic overactive bladder. This drug is safe to use in both Parkinson’s disease and multiple sclerosis, considering the low risk of cognitive impairment in polypharmacy.

Full Text

Restricted Access

About the authors

E. S Korshunova

FGBNU Research Center of Neurology; FGBU “Central state medical academy” of Administrative Directorate of the President of Russian Federation; A.I. Evdokimov’s Moscow State University of Medicine and Dentistry

Email: e_korshunova@mail.ru
Ph.D., associate professor

M. N Korshunov

FGBU “Central state medical academy” of Administrative Directorate of the President of Russian Federation

PhD, associate professor

E. P Nuzhnyi

FGBNU Research Center of Neurology

Ph.D.

I. V Zakroyshchikova

FGBNU Research Center of Neurology

Ph.D.

A. Kh Zabirova

FGBNU Research Center of Neurology

Ph.D. student

D. M Korshunov

A.I. Evdokimov’s Moscow State University of Medicine and Dentistry

student

N. A Suponeva

FGBNU Research Center of Neurology

Ph.D., MD, Professor

S. P Darenkov

FGBU “Central state medical academy” of Administrative Directorate of the President of Russian Federation

h.D., MD, Professor, Head of the Department of Urology

References

  1. Филиппова Е.С., Борзунов И.В., Баженов И.В. Дисфункция нижних мочевыводящих путей у неврологических больных. Уральский медицинский журнал. 2019;5(173):169-172. doi: 10.25694/URMJ.2019.05.43
  2. Коршунова Е.С., Коршунов М.Н., Даренков С.П. Нейрогенный и идиопатический гиперактивный мочевой пузырь: камни преткновения. Consilium Medicum 2019;21(7):53-57. doi: 10.26442/20751753.2019.7.190384
  3. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте: Методическое пособие для врачей. М., 2005
  4. Andersson K.E., Cardozo L., Cruz F., Lee K.S., Sahai A., Wein A.J. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence 6th edition. 2017:805-957. doi: 10.1046/j.1464-410x.1999.00397.x.
  5. Kay G.G., Granville L.J. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly Clin Ther. 2005;27(1):127-138. doi: 10.1016/j.clinthera.2005.01.00.
  6. Ziad S. Nasreddine, Natalie A. Phillips, Valerie Bedirian, Simon Charbonneau, Victor Whitehead.The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment (англ.). Journal of the American Geriatrics Society. 2005;53(4):695-699. ISSN 1532-5415. doi: 10.1111/j.1532-5415.2005.53221.x.
  7. Rudy D., Cline K., Harris R., Goldberg K., Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int. 2006;97(3) :540-546. Doi:10. 1111/j.1464-410X.2006.06035.x.
  8. https://www.who.int/ru/news/item/30-09-2015-who-number-of-people-over-60-years-set-to-double-by-2050-major-societal-changes-required
  9. Milsom I., Coyne K.S., Nicholson S., Kvasz M, Chen C.I., Wein A.J. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79-95. Doi: 10.1016/j. eururo.2013.08.03.1
  10. Штульман Д.Р., Левин О.С. Умеренные когнитивные нарушения... Справочник практического врача. 4-е изд. М.: Медпресс-информ, 2005
  11. Callegari E., Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, LaPerle JL, Michel MC, Kay GG. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011 ;72(2):235-246. doi: 10.1111/j.1365-2125.2011.03961.x
  12. Коршунова Е.С., Коршунов М.Н. Гиперактивный мочевой пузырь у мольтиморбидных больных. Что нужно помнить? Consilium Medicum. 2018;20(7):41-45
  13. Geller E.J., Crane A.K., Wells E.C., et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig. 2012;32(10):697-705. doi: 10.2165/11635010 000000000-00000
  14. Staskin D., Kay G., Tannenbaum C., Goldman H.B., Bhashi K., Ling J., Oefelein M.G.Trospium Chloride Has No Effect on Memory Testing and Is Assay Undetectable in the Central Nervous System of Older Patients with Overactive Bladder. Int J Clin Pract 2010;64:1294-1300. doi: 10.1111/j.1742-1241.2010.02433.x
  15. Araklitis G., Robinson D., Cardozo L. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. Clinical Interventions in Aging 2020;15:1493-1503. doi: 10.2147/CIA.S252852
  16. Ivchenko A., Bodeker R.H., Neumeister C. et al. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective noninterventional study. BMC Urol. 2018;18(80). Doi.org/10.1186/s12894 018-0394-8
  17. Zaharova M.N. et al. Multiple sclerosis: issues of diagnosis and treatment. M., Media Mente. 2018. 240 p. Russian (Захарова М.Н. и соавт. Рассеянный склероз: вопросы диагностики и лечения. М., Медиа Менте. 2018. 240 с. ISBN 978-5-9907487-9-8).
  18. Guay D.R.P. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42:1243-1285. doi: 10.2165/00003088-200342140-00004.
  19. Ohtake A., Saitoh C., Yuyama H. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull. 2007;30:54-58. Doi: 10.1248/ bpb.30.54.
  20. Chapple C.R., Khullar V., Gabriel Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543-562. doi: 10.1016/j.eururo.2008.06.047.
  21. Ortiz de Montellano, Paul R. Cytochrome P450: structure, mechanism, and biochemistry. 3rd edition. New York: Kluwer Academic/Plenum Publishers, 2005. ISBN 0-306-48324-6.
  22. Crewe H.K., Lennard M.S., Tucker G.T. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992/09/01 ed. Br J Clin Pharmacol. 1992;34:262-265.
  23. Yaich M., Popon M., Medard Y. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacog enetics.1998;8(5):449-451.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies